GSTM1 and chronic kidney disease: The Kidney Disease Outcomes Quality Initiative (KDOQI) work group pooled the results of six related studies, and it showed that groups with higher Hb targets yielded a relative risk (RR) (95% CI) of 1.24 (1.02, 1.51) on adverse cardiovascular events in patients with non-dialysis CKD.